In relation to COVID-19, from April 3rd onward people aged 75 years and older, residents in care homes for older people, and those aged 5 years and over with a weakened immune system [were] offered a booster of coronavirus (COVID-19) vaccine [in] spring’.1 A dose of Sanofi’s VidPrevtyn Beta COVID-19 vaccine is being offered by the NHS for free.2 The elderly in our communities who face language barriers with regard to the details of the vaccine are likely to seek the opinion of their children and grandchildren. There are nearly 12 million (11,989,322) people aged 65 and above in the UK of which 5.4 million people are aged 75+; 1.6 million are aged 85+; Over 500,000 people are 90+ (579,776); and 14,430 are centenarians.3 Family members consequently might consult medical and Islamic sources. For all parties involved in the decision-making process, an informed decision is crucial.

As the VidPrevtyn Beta vaccine is intramuscular, receiving it is not considered to affect the validity of one’s fast.4 The vaccine is taken to strengthen immunisation; its contents neither reach the stomach nor provide any significant amount of nutrition. A single vial contains 0.5 ml which includes the colourless antigen a the whitish milky adjuvant emulsion.5 One must bear in mind, however, that receiving a vaccine could cause minor short-lasting (less than 3 days) side effects of mild to moderate severity such as fever.5 The side effects might affect one’s ability to fast for the next few days. Potential side effects could include injection site pain, headache, myalgia (muscle aches and pain), arthralgia (pain in a joint), and chills.5

The NHS is patient-centred and as such, individuals are being offered a choice to either accept the VidPrevtyn Beta vaccine or choose the Pfizer BA.4/5 or Moderna vaccines. The AstraZeneca vaccine is no longer being supplied for routine use in the UK due to high risk of myocarditis.6

The main reason for the MHRA to supply the nation with the VidPrevtyn Beta vaccine is that it would trigger a better immune response in patients over 75 years of age and lead to stronger immunity. This vaccine therefore is hoped to be more effective than the Pfizer and Moderna vaccines. The key ingredient added to this vaccine is the adjuvant squalene. An adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in immune compromised populations; the inclusion of an adjuvant would help to boost the inherently weak immune response and has shown to be effective in the very young and the very old.10,11 As such, adjuvants help the vaccines to be more effective. The adjuvant used in the VidPrevtyn Beta vaccine is the organic compound squalene.

A variety of sources produce squalene such as olives and rice, however, shark liver produces an oil that is most effective as an adjuvant.12 sources would pose no objections permissibility in terms of ingredients, its use in vaccines is limited. Yielding an amount of 50 kg of phytosqualene would require a hectare of land planted with olive trees The extensive and laborious oil refining processing also involves high financial costs. extracting squalene from shark liver oil is a process that is much simpler and cheaper. Over 98% of pure squalene can be extracted from shark liver oil in a single distillation.13

Synthetic squalene is another a high demand is required for a vaccine, a bottleneck could form as a result of the uncertainty of the quantity as well as unavailability.16 If squalene from other sources is to be used, extraction methods would need to ensure that purity level matches the purity level of squalene from shark liver oil, which is 99% pure. As such, due to its stability-enhancing properties and biocompatibility, a national drive is in effect to promote the squalene COVID-19 vaccines for the elderly and compromised populations. Nevertheless, with growing concerns around the depletion of wild sharks, industries are likely to move toward squalene from genetically engineered organisms, such as yeast and bacteria.18

The VidPrevtyn Beta vaccine is also the recommended vaccine for patients that are allergic to mRNA vaccines such as Pfizer and Moderna. An allergic reaction to mRNA vaccines could result in anaphylactic reactions such as experiencing abdominal cramps, fast heart rate, swollen eyes and face, red itchy rashes, wheezing, and fainting. VidPrevtyn Beta has shown efficacy as aprimary and as a booster vaccine in adults who had received primary vaccination with either mRNA.

If a patient wishes to have the Nuvaxovid COVID vaccine then specific clinical criteria must be fulfilled before a healthcare professional can recommend that the patient is given the Nuvaxovid vaccine. Moreover, the Nuvaxovid vaccine would be in a controlled environment; after consultation with a health exper hospital. A post-vaccination observation of the patient would also be required by a health expert for 30 minutes.19 Moreover, patients wishing to have alternative vaccines would be expected to make their own arrangements to reach designated location vaccines are offered. Patients also need to bear in mind that alternative vaccines are now also limited. Moreover, the PHE has stated that ‘From the end of the spring 2023 campaign, the primary course of COVID becomes a targeted offer to those at higher risk and only during seasonal campaigns. The main exception to this would be unvaccinated individuals aged five years and above who become or have recently become severely immunosuppressed’.5

With regards to the shark oil squalene in patients might have questions from an Islamic jurisprudential viewpoint with regard to its permissibility. According to the majority of Sunni schools (Maliki, Shafi, and Hanbali), all marine creatures are permitted for consumption including sharks from the genus squalus. The Sunni Hanafi school, on the other hand, consider fish to be permissible for consumption whereas the Shia Ja’fari school permit only scaled fish.  Nevertheless, a pertinent point to note in relation to consumption is that omega tablets are not the same as vaccines. Whereas the former is consumed for nutritional purposes, vaccines are injected for immunisation. For patients with weak systems who require the vaccine to help strengthen their immunity, and for whom squalene is the best medical option, the vaccine would be permitted due to necessity. The necessity to resort to shark squalene in vaccines, hopefully, is temporary.

Nevertheless, for Muslims who are concerned about squalene’s nutritional value,21 arguably invalidate the fast. Patients with weak immune systems, however, are advised by the Qur’an (2:185) to postpone fasting until they can fast healthily. The nutritional value of theVidPrevtyn Beta vaccine and its impact on the validity of fasting are points that patients and Muslim jurists might want to discuss further. As such, rulings related to consumption are inapplicable to vaccines. On that note, Seqirus’s flu vaccine Fluad, which is offered to the elderly over the age of 65 al contains squalene22,23,24,25 and has been received by Muslim patients. The percentage of patients aged 65 years and over of South Asian ethnicity in England who received the seasonal influenza vaccine in 2022  include 72% Asian or British Asian IndiBritish Asian Pakistani, and 68% of Asian or Asian British Bangladeshi.26

Returning to the point of providing advice to the elderly, Rasulullah (Salla Allahu alayhi waalihi wasallam)reminded us that the one whose advice is sought is accountable. As such, Muslim jurists are advised to be fully informed regarding the details of the vaccines by consulting health care professionals or to signpost questioners to the best source of medical advice. Due to fears around fertility, whilst males have en  benefits of vaccination, by contrast, females have beendeprived. As such, the autonomy of female patients is also crucial.

Muslim families and Muslim faith leaders are advised to educate themselves and the community concerning the VidPrevtyn Beta vaccine. When the NHS offers the vaccine to the elderly, with accurate information, patients would be able to make an informed decision. The elderly in our communities are vulnerable. through the means of the NHS COVID programme, we are fortunate to continue enjoying the company of the elderly in our community. According to PHE, ‘approximately 46,500 admissions were prevented in those aged 65 to 74, 73,800 in those aged 75 to 84, and 58,600 in those aged 85 and over’.  the vaccination programme, we pray that our elders remain safe and healthy bi’idhnillah


I wish to acknowledge Ashraf Karbhari (Registered Nurse, Lead Nurse for the Covid-19 Vaccination Programme and NHS Lancashire and South Cumbria Integrated Care Board); Imam Yunus Dudhwala (Head of Chaplaincy, Barts Health NHS Trust London); and Dr Salman Waqar (General Practitioner and Academic Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford) for their consultation and invaluable feedback.


  1. NHS. A guide to the COVID-19 spring booster 2023
    [Internet]; 2023, Mar 9 [cited 2023, Mar 26]. Available
  2. NHS England. Preparing for a successful spring 2023
    COVID-19 booster campaign [Internet]; 2023, Feb 24
    [cited 2023, Mar 26]. Available from:
  3. Age UK. Later Life in the United Kingdom 2019
    [pdf]. 2019, May [cited 2023, Mar 29]. Available from:
  4. Maravia, U. COVID-19 Intra-muscular vacci
    during Ramadan: Vaccines whilst fasting. Journal of the
    British Islamic Medical Association. 2021, 7(3), 3
  5. UK Health Security Agency. The Green Book:
    Chapter 14a – COVID-19 – SARS-CoV
    Mar 9 [cited 2023, Mar 29]. Available from
  6. GOV UK. Myocarditis and pericarditis after COVID
    19 vaccination: clinical management guidance for
    healthcare professionals [Internet]; 2023, Jan 09 [cited
    2023, Mar 26]. Available from:
  7. GOV UK. Sanofi Pasteur COVID
    authorised by MHRA [Internet]; 2022, Dec 21 [cited
    2023, Mar 26]. Available from:
  8. Centers for Disease Control and Prevention What is
    an adjuvant and why is it added to a vaccine [Internet];
    2022, Sep 27 [cited 2023, Mar 26]. Available from:
  9. Soema, P., Kompier, R., Amorij, J. and Kersten, G.
    Current and next generation influenza vaccines:
    formulation and production strategies. European Journal
    of Pharmaceutics and Biopharmaceutics. 2015, 94, 251
  10. Dikow, R., Eckerle, I., Ksoll
    H., Schwenger, V., Zeier, M., Schnitzler, P. and
    Sommerer, C. Immunogenicity and Efficacy in
    Hemodialysis Patients of an AS03(A)
    Vaccine for 2009 Pandemic Influenza A(H1N1): A
    Nonrandomized Trial.Original Investigation Dialysis.
    2011, 57(5), 716-723.
  11. Siegrist, C-A. and Aspinall, R. B
    Vaccination at the Extremes of Age. Nature Reviews
    Immunology. 2009, 9, 185-94.
  12. Nguyen-Contant, P., Sangster, M.Y. and Topham,
    D.J. Squalene-Based Influenza Vaccine Adjuvants and
    Their Impact on the Hemagglutinin
    Response. Pathogens. 2021, 10(3),355,
  13. Ciriminna, R., Pandarus, V., Béland, F. and
    Pagliaro, M. Catalytic Hydrogenation of Squalene to
    Squalane [pdf]; 2014, August 29 [cited 2023, March 28].
    Available from:
  14. Lozano-Grande, M.A., Gori
    Rangel, E., Dávila-Ortiz, G. and Martínez
    Plant Sources, Extraction Methods, and Uses of Squalene
    [Internet]; 2018, Aug 01 [cited 2023, Mar 28]. Available
  15. Popa, O., Bəbeanu, N.E., Popa, I., Ni
    Pârvu, C.E. Methods for Obtaining and Determination of
    Squalene from Natural Sources. BioMed Research
    International. 2015, 1-16.
  16. Chatterjee, S., Dey, S., Nandy, A. and Basak, S.C. A
    Computational Search for Peptide Vaccines Using Novel
    Mathematical Descriptors of Sequences of Emerging
    Pathogens. In: Anil K.S. (ed.). Biophysical and
    Computational Tools in Drug Discovery. Cham,
    Switzerland: Springer Nature; 2020. pp.194
  17. Gohil, N., Bhattacharjee, G., Khambhati, K.,
    Braddick, D. and Singh, V. Engineering Strategies in
    Microorganisms for the Enhanced Production of
    Squalene: Advances, Challenges and Opportunities.
    Frontiers in Bioengineering and Biotechnology. 2019,
    7(50), 1-24.
  18. McPhee, D., Pin, A., Kizer, L. and Perelman, L.
    Deriving Renewable Squalane from Sugarcane [Internet];
    2014, Jul 17 [cited 2023, Mar 29]. Available from:
  19. MHRA. Decision: Last updated 11/2022
    Information Leaflet (PIL) for Nuvaxovid dispersion for
    injection [Internet] 2022, Nov 9 [cited 2023, Mar 29].
    Available from:
  20. Khamenei, A. 9320-7: Permissibility of eat
    clams, and mussels [Internet]; 1999 [cited 2023, Mar 28].
    Available from:
  21. University of Oxford. Vaccine ingredient. [Inte
    2022, May 26 [cited 2023, Mar 29]. Available from:
  22. Dupuis, M., McDonald, D.M. and Ott, G.
    Distribution of Adjuvant MF59 and Antigen GD2 after
    Intramuscular Injection in Mice. Vaccine. 1999, 18(5
  23. Ko, E.J., Lee, Y.T., Kim, K.H , Jung, Y.J., Lee, Y.,
    Denning, T.L and Kang, S.M. Effects of MF59 Adjuvant
    on Induction of Isotype-Switched IgG An
    Protection after Immunization with T
    Influenza Virus Vaccine in the Absence of CD4+ T
    Cells. Journal of Virology. 2016, 90(15), 697
  24. Seubert, A., Monaci, E., Pizza, M., O’Hagan, D.T.
    and Wack, A. The Adjuvants Aluminum Hydr
    MF59 Induce Monocyte and Granulocyte
    Chemoattractants and Enhance Monocyte Differentiation
    toward Dendritic Cells. Journal of Immunology. 2008,
    180(8), 5402-12.
  25. Vono, M., Taccone, M., Caccin, P., Gallotta, M.,
    Donvito, G., Falzoni, S., Palmi
    Rappuoli, R., Di Virgilio, F. and De Gregorio, E. The
    Adjuvant MF59 Induces ATP Release from Muscle That
    Potentiates Response to Vaccination. The Proceedings of
    the National Academy of Sciences. 2013, 110(52),
  26. GOV UK. Seasonal influenza vaccine uptake
    amongst GP patients in England 2022 to 2023
    [Spreadsheet] 2023, Feb 28 [cited 2023, Feb 29].
    Available from:
  27. Public Health England. COVID
    surveillance report published [Internet]; 2021, May 14
    [cited 2023, Mar 28]. Available from: